Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

26 analysts have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $650.00 to $1,050.00. On average, they expect the company's share price to reach $904.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of the year. Since then, REGN stock has increased by 15.3% and is now trading at $831.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REGN earnings forecast.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 earnings per share for the quarter, beating analysts' consensus estimates of $8.48 by $1.76. The biopharmaceutical company earned $3.16 billion during the quarter, compared to analyst estimates of $3.02 billion. Regeneron Pharmaceuticals had a net margin of 33.93% and a trailing twelve-month return on equity of 19.19%. Regeneron Pharmaceuticals's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $9.77 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Subversive Mental Health ETF (SANE) and 2ndVote Life Neutral Plus ETF (LYFE).

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (67.91%), BlackRock Inc. (8.28%), Capital World Investors (5.06%), State Street Corp (4.60%), Capital International Investors (2.69%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $831.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $90.28 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis.

The company employs 12,256 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.